By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cubist Pharmaceuticals, Inc. 

65 Hayden Avenue

Lexington  Massachusetts  02421  U.S.A.
Phone: 781-860-8660 Fax: 781-861-0566


SEARCH JOBS
There’s something special about working at Cubist Pharmaceuticals.

We provide a progressive, flexible work environment and a highly competitive total rewards program designed to meet your work/life needs now and in the future. In our product, our pipeline and in our supportive culture, Cubist demonstrates its continuing commitment of excellence to our employees and our shareholders.

Cubist is a bio-pharmaceutical company focused on the research, commercial¬ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment. CUBICIN® , (daptomycin for injection), our marketed product, has been used in the treatment of more than an estimated 1.1 million patients with serious and sometimes life-threatening infections. CUBICIN has generated hundreds of millions of dollars in annual sales that helped propel Cubist into one of the Commonwealth's best-performing firms as evidenced by recent recognition. Cubist was ranked among Top Pharmas on the Scrip 100 List, while Forbes recently listed Cubist as one of 14 "Productivity Powerhouses." Cubist appeared in The Boston Globe's 2010 annual list of the "Top Places to Work" in Massachusetts (for the third consecutive year).

Mass High Tech announced that Cubist ranked 13th among the top 30 Fastest-Growing Public Technology Companies in New England for 2010 and was one of only ten pharmaceutical companies to make that list. Cubist also debuted as the 31st overall company and top pharmaceutical company named to FORTUNE's 2010 List of 100 Fastest-Growing Companies, and was named to the 2010 Deloitte Technology Fast 500™ for the sixth consecutive year.


Key Statistics


Email: ir@cubist.com
Ownership: Public

Web Site: Cubist Pharmaceuticals, Inc.
Employees: ~600
Symbol: CBST
 









Company News
Merck & Co. (MRK) Begins Tender Offer To Acquire Cubist Pharmaceuticals, Inc. (CBST) 12/19/2014 9:15:31 AM
Cubist Pharmaceuticals, Inc. (CBST) Comments On CUBICIN Patent Litigation 12/9/2014 10:46:41 AM
Survey of Investors, Hedge Funds Blasé on Merck & Co. (MRK), Cubist Pharmaceuticals, Inc. (CBST) Deal 12/8/2014 3:38:43 PM
Drug Giant Merck & Co. (MRK) Buys Cubist Pharmaceuticals, Inc. (CBST) For $9.5 Billion 12/7/2014 8:13:01 PM
Here's Why Roche (RHHBY) Might Buy Watertown's Tetraphase — And Why Cubist Pharmaceuticals, Inc. (CBST) Probably Won't 12/1/2014 5:57:32 AM
Cubist Pharmaceuticals, Inc. (CBST) Names Dr. Patrick Vink Chief Operating Officer 11/5/2014 10:06:29 AM
Cubist Pharmaceuticals, Inc. (CBST) To Present At Jefferies 2014 Healthcare Conference 11/3/2014 10:10:00 AM
Cubist Pharmaceuticals, Inc. (CBST) Reports Third Quarter 2014 Financial Results 10/22/2014 9:38:44 AM
Cubist Pharmaceuticals, Inc. (CBST) Brings In Ex-Biogen Idec (BIIB) Exec For CEO Post 10/20/2014 5:44:38 AM
Cubist Pharmaceuticals, Inc. (CBST) To Announce Third Quarter 2014 Financial Results On Tuesday, October 21, 2014 10/14/2014 11:46:58 AM
12345678910...
//-->